Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Remogliflozin Etabonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remogliflozin Etabonate SCHEMBL721678 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL16421581 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL15168697 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL10081649 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL18432846 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL10066609 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL17034638 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL14634764 | 0.98 | SLC5A2 (0.95) | SLC5A2SLC5A1 | |
| SCHEMBL14634761 | 0.98 | SLC5A2 (0.95) | SLC5A2SLC5A1 | |
| SCHEMBL877233 | 0.98 | SLC5A2 (0.95) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283100-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | IC MEDTECH CORP (US) | 2021-09-16 | — | — | US | disclosed |
| US-10940159-B2 | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin | ISLET SCIENCES | 2021-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283100-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | SLC5A1, SLC5A2, SLC5A6 | SLC5A2 2/4885SLC5A1 1/4885 |
| US-10940159-B2 | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin | GLP1R, SLC5A2, SI | SLC5A2 2/4885SLC5A1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.